Floatz logo

Belzutifan

Renal Cell Carcinoma

Vall d'Hebron Institute of OncologySmall moleculePhase 3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

270 Active assets in the Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Pazopanib
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Cyclosporin A
National Cancer Institute (NCI)
Phase 2BB
INTERFERON-ALFA-2A
Central European Society for Anticancer Drug Research
Phase 3BB
Everolimus
Merck Sharp & Dohme LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Belzutifan is also rated in:

von Hippel-Lindau diseaseActive
BB
Indicative · Phase 3
64 / 100
View asset →
clear cell renal carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
nonpapillary renal cell carcinomaActive
CCC
Indicative · Phase 2
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →